ARIDIS PHARMACEUTICALS INC
ARIDIS PHARMACEUTICALS INC
Action · US0403341045 · ARDS (XNAS)
Aperçu Indicateurs financiers
0,0001 USD
NASDAQ (XNAS) · Cours et graphiques actuels sur MoneyPeak
06.06.2025 16:21

Cours actuels de ARIDIS PHARMACEUTICALS INC

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
ARDS
USD
06.06.2025 16:21
0,0001 USD
0,0001 USD

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
0,00 % 0,00 % 0,00 % 0,00 % -50,00 % -99,85 % -100,00 %

Profil de l'entreprise pour ARIDIS PHARMACEUTICALS INC Action

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

Données de l'entreprise

Nom ARIDIS PHARMACEUTICALS INC
Société Aridis Pharmaceuticals, Inc.
Symbole ARDS
Site web https://www.aridispharma.com
Marché d'origine XNAS NASDAQ
ISIN US0403341045
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Vu L. Truong Ph.D.
Pays États-Unis d'Amérique
Devise USD
Employés 0,0 T
Adresse 983 University Avenue, 95032 Los Gatos
Date d'introduction en bourse 2018-08-14

Symboles boursiers

Nom Symbole
NASDAQ ARDS

Autres actions

Les investisseurs qui détiennent ARIDIS PHARMACEUTICALS INC ont également les actions suivantes dans leur portefeuille :
DEKA STUFENZINS ANL 18/28
DEKA STUFENZINS ANL 18/28 Obligation
NORDLB 21/33
NORDLB 21/33 Obligation
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025